Comprehensive resources and coverage so you and your patients can focus on treatment

Administering Euflexxa

Watch how you can help deliver the full benefit of EUFLEXXA with 3 injections over 3 weeks.
Injection Instructions

Office Materials

Here are some helpful resources to assist you and your patients in understanding what to expect from EUFLEXXA.
Want these resources on-hand in your office?
Order now
Patient
Brochure
Post-injection
Instructions

Dual-Acting Effects

Find out how EUFLEXXA may help your patients’ OA knee pain in two ways.

Discover the Effects

Get Euflexxa

See how getting treatment for your
patients can be easy convenient.

Learn More
  1. Rolling 12 month average of IQVIA claims data based on unique patients (December 2022).

Access

Most commercially insured patients can get EUFLEXXA under their medical benefits.

Preferred formulary status by many of the largest commercial plans with
fewer access restrictions*

EUFLEXXA is covered under the pharmacy benefit by many insurers such as UnitedHealthcare, OptumRx, Express Scripts, and the Veterans Administration.

*Subject to change based on individual plan coverage. Check the member’s benefits for more details.

~50% of Commercially Insured Patients Pay A
on Medicare Part B
without restrictions

*Subject to change based on individual plan coverage. Check the member’s benefits for more details.

Practices that utilized the hub for their initial benefits investigation saw 99% of their claims approved 2
Enroll Today

Euflexxa Solution Center

A hub that streamlines everything from insurance verification to patient support

Helps you and your staff navigate the coverage landscape¶# with comprehensive programs that

connect patients with support

Benefits investigations are completed within 24 hours while you track progress online

For Solution Center questions call 1-866-383-5391 or fax 1-866-383-5392.

Patient Direct Program

A program that provides access for patients who are underinsured or uninsured.

Available to a wide range of patients.

See eligibility criteria

Quick and easy to enroll via fax or through the

EUFLEXXA Solution Center

Managed by CareMed

Euflexxa Commitment

If your patient is not satisfied with their OA knee pain relief 10 weeks after their last EUFLEXXA injection, we offer up to a $100 refund for copay costs. The patient must have received 1 EUFLEXXA injection a week for 3 weeks between the eligibility period.

Offer Terms and Conditions apply

To receive the refund, we need the following information no later than 14 weeks after the patient’s last injection to process their refund:

  1. Completed refund form
  2. Explanation of Benefits for each injection from the insurance company
  3. Receipts for their EUFLEXXA copay payment
  4. Fax the documents to 1-866-383-5392

†Preferred access refers to favorable formulary status, medical policy, or fewer restrictions for EUFLEXXA.

‡Allowed for buy and bill.

§BCBS IL, BCBS MT, BCBS NM, BCBS OK, and BCBS TX.

The Solution Center will respond to each fax submission within 24 hours, notifying you of a patient’s coverage via the Benefits Investigation Report.

#The EUFLEXXA Solution Center does not file claims or appeal claims, and cannot guarantee that you will be successful in obtaining reimbursement. Third-party payment for medical products and services is affected by numerous factors, none of which can be anticipated or resolved by the Solution Center.

Dual-Acting Effects

Find out how EUFLEXXA may help your patients’ OA knee pain in two ways.

Discover the Effects

Get Euflexxa

See how getting treatment for your
patients can be easy convenient.

Learn More
  1. Rolling 12 month average of IQVIA claims data based on unique patients (December 2022).
  2. Data on file. Ferring Pharmaceuticals Inc. (December 2022).

Please see Important Safety Information and Full Prescribing Information

Indication

EUFLEXXA® [1% sodium hyaluronate] is indicated for the treatment of pain in osteoarthritis [OA] of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics [eg, acetaminophen].

Important Safety Information

  • EUFLEXXA is contraindicated in patients who have a known hypersensitivity to hyaluronate preparations or who have knee joint infections, infections, or skin disease in the area of the injection site.
  • EUFLEXXA should not be administered through a needle previously used with medical solutions containing benzalkonium chloride. Do not use skin disinfectants for skin preparation that contain quaternary ammonium salts.
  • Do not inject intravascularly due to potential for systemic adverse events.
  • The safety and effectiveness of injection in conjunction with other intra-articular injectables, or into joints other than the knee have not been studied. Remove any joint effusion prior to injecting. Transient pain or swelling of the injected joint may occur after intra-articular injection with EUFLEXXA.
  • The most common adverse events related to EUFLEXXA injections reported in 12- and 26-week clinical studies were arthralgia, back pain, pain in extremity, musculoskeletal pain, and joint swelling. In an open-label extension of the 26-week clinical study with repeat series of injections, the most common adverse events related to EUFLEXXA at Week 52 were arthralgia and joint swelling.

Please see full Prescribing Information

Indication

EUFLEXXA® [1% sodium hyaluronate] is indicated for the treatment of pain in osteoarthritis [OA] of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics [eg, acetaminophen].

Important Safety Information

  • EUFLEXXA is contraindicated in patients who have a known hypersensitivity to hyaluronate preparations or who have knee joint infections, infections, or skin disease in the area of the injection site.
  • EUFLEXXA should not be administered through a needle previously used with medical solutions containing benzalkonium chloride. Do not use skin disinfectants for skin preparation that contain quaternary ammonium salts.
  • Do not inject intravascularly due to potential for systemic adverse events.
  • The safety and effectiveness of injection in conjunction with other intra-articular injectables, or into joints other than the knee have not been studied. Remove any joint effusion prior to injecting. Transient pain or swelling of the injected joint may occur after intra-articular injection with EUFLEXXA.
  • The most common adverse events related to EUFLEXXA injections reported in 12- and 26-week clinical studies were arthralgia, back pain, pain in extremity, musculoskeletal pain, and joint swelling. In an open-label extension of the 26-week clinical study with repeat series of injections, the most common adverse events related to EUFLEXXA at Week 52 were arthralgia and joint swelling.

Please see full Prescribing Information

©2024 Ferring B.V. All rights reserved.
US-EU-2300033

Patient eligibility criteria for Patient Direct Program

  • Must be 18 years of age or older and have a valid EUFLEXXA prescription
  • Must be a resident of the United States or US territories, except residents of Massachusetts are not eligible for this program
  • Must be uninsured or have commercial insurance only. Those participating in any federal or state healthcare program, including without limitation Medicare, Medicaid, the Department of Veterans Affairs healthcare program, TRICARE, and any federal or state employee benefit program are not eligible for the program
  • Additional terms and conditions apply

Offer Terms and Conditions

  • This offer is not valid for any other Ferring Pharmaceuticals Inc product. Fax-in only. No mail, phone, or emailed requests will be honored
  • Ferring Pharmaceuticals is not responsible for lost, late, damaged, misdirected, incomplete or illegible submissions
  • The value of this refund may not exceed the amount of patient’s responsibility (copay) for the prescription. Maximum refund amount is $100
  • Offer limited to cash-paying or commercial US residents who received three (3) injections of EUFLEXXA within 21 days as indicated (ie, one injection a week for 3 weeks and are undergoing their first EUFLEXXA treatment regimen)
  • Refund claims must be received between 10 and 14 weeks after the last injection
  • Limit one refund per eligible patient
  • Ferring Pharmaceuticals reserves the right to cancel, modify, or rescind the program at any time
  • The patient responsibility (copay) for the injection administration and/or EUFLEXXA must be isolated on the claim. Office visits or other ancillary costs included in patient’s responsibility are excluded from refund amount
  • This offer is void where prohibited or restricted by law. Offer not valid for prescriptions and/or services reimbursed in whole or in part by any federal or state healthcare program, including without limitation Medicare, Medicaid, Department of Veterans Affairs healthcare program, TRICARE, and any federal or state employee benefit program
  • Please retain copies of the materials you submit. All submissions become the property of a Ferring Pharmaceuticals contracted third-party vendor
  • Patient must fully complete and follow instructions as stated on the claim form
  • Tampering with, altering, or falsifying payment information constitutes fraud
  • Please allow 4-6 weeks for delivery of refund check. Refund check will be issued in US dollars

You have selected to go to the
healthcare professional website.

Are you a US healthcare professional?

Yes No

Get materials for you and your patients

To receive educational information, complete the form below and submit for printed materials.

25 per pack
25 per pack
Hidden

Section Break

Email(Required)
Address(Required)

Injection Techniques

This website may contain links to, or be accessed from links on, other worldwide websites. Ferring does not have responsibility for or control the contents, availability, operation or performance of other websites to which this website may be linked or from which this website may be accessed.

Ferring makes no representation regarding the content of any other websites which you may access from this website.

Ok Cancel